Simon Yadgir1, Catherine Owens Johnson1, Victor Aboyans2,3, Oladimeji M Adebayo4, Rufus Adesoji Adedoyin5, Mohsen Afarideh6, Fares Alahdab7, Alaa Alashi8, Vahid Alipour9,10, Jalal Arabloo9, Samad Azari9, Celine M Barthelemy1, Catherine P Benziger11, Adam E Berman12, Ali Bijani13, Juan J Carrero14, Félix Carvalho15,16, Ahmad Daryani, Andre R Durães17,18, Alireza Esteghamati6, Talha A Farid19, Farshad Farzadfar20, Eduarda Fernandes21, Irina Filip22,23, Mohamed M Gad8,24, Samer Hamidi25, Simon I Hay1,26,2, Olayinka Stephen Ilesanmi27, Seyed Sina Naghibi Irvani28, Mikk Jürisson29, Amir Kasaeian30,31, Andre Pascal Kengne32,33, Abdur Rahman Khan19, Adnan Kisa34,35, Sezer Kisa36, Dhaval Kolte37, Navid Manafi38,39, Amir Manafi40, George A Mensah33,41, Erkin M Mirrakhimov42,43, Yousef Mohammad44, Ali H Mokdad1,45, Ruxandra Irina Negoi46,47, Huong Lan Thi Nguyen48, Trang Huyen Nguyen49, Molly R Nixon1, Catherine M Otto50, Shanti Patel51, Thomas Pilgrim52, Amir Radfar53,54, David Laith Rawaf55,56, Salman Rawaf57,58, Wasiq Faraz Rawasia59, Aziz Rezapour9, Leonardo Roever60, Anas M Saad61, Seyedmohammad Saadatagah62, Subramanian Senthilkumaran63, Karen Sliwa33, Berhe Etsay Tesfay64, Bach Xuan Tran65, Irfan Ullah66,67, Muthiah Vaduganathan68, Tommi Juhani Vasankari69, Charles D A Wolfe70,71, Naohiro Yonemoto72, Gregory A Roth1,45,50. 1. Institute for Health Metrics and Evaluation (S.Y., C.O.J., C.M.B., S.I.H., A.H.M., M.R.N., G.A.R.), University of Washington, Seattle. 2. Department of Cardiology, Dupuytren University Hospital, Limoges, France (V. Aboyans). 3. Institute of Epidemiology, University of Limoges, France (V. Aboyans). 4. College of Medicine, University College Hospital, College of Medicine, University College Hospital, Ibadan, Oyo, Nigeria (O.M.A.). 5. Department of Medical Rehabilitation, Obafemi Awolowo University, Ile-Ife, Osun State, Nigeria (R.A.A.). 6. Endocrinology and Metabolism Research Center (M.A., A.E.), Tehran University of Medical Sciences, Iran. 7. Evidence Based Practice Center, Mayo Clinic Foundation for Medical Education and Research, Rochester, MN (F.A.). 8. Department of Cardiovascular Medicine (A.A., M.M.G.), Cleveland Clinic, OH. 9. Health Management and Economics Research Center (V. Alipour, J.A., S.A., A. Rezapour), Iran University of Medical Sciences, Tehran. 10. Health Economics Department (V. Alipour), Iran University of Medical Sciences, Tehran. 11. Heart and Vascular Center, Essentia Health, Duluth, MN (C.P.B.). 12. Department of Medicine, Medical College of Georgia at Augusta University (A.E.B.). 13. Social Determinants of Health Research Center, Babol University of Medical Sciences, Mazandaran, Iran (A.B.). 14. Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden (J.J.C.). 15. Applied Molecular Biosciences Unit (F.C.), University of Porto, Portugal. 16. Institute of Public Health (F.C.), University of Porto, Portugal. 17. Toxoplasmosis Research Center, Mazandaran University of Medical Sciences, Sari, Iran (A.D.). 18. School of Medicine, Federal University of Bahia, Salvador, Brazil (A.R.D.). 19. Division of Cardiovascular Medicine, University of Louisville, KY (T.A.F., A.R.K.). 20. Non-communicable Diseases Research Center (F.F.), Tehran University of Medical Sciences, Iran. 21. REQUIMTE/LAQV (E.F.), University of Porto, Portugal. 22. Psychiatry Department, Kaiser Permanente, Fontana, CA (I.F.). 23. Department of Health Sciences, A.T. Still University, Mesa, AZ (I.F.). 24. Gillings School of Global Public Health, University of North Carolina Chapel Hill (M.M.G.). 25. School of Health and Environmental Studies, Hamdan Bin Mohammed Smart University, Dubai, United Arab Emirates (S.H.). 26. School of Medicine (S.I.H.), University of Washington, Seattle. 27. Department of Community Medicine, University of Ibadan, Nigeria (O.S.I.). 28. Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran (S.S.N.I.). 29. Institute of Family Medicine and Public Health, University of Tartu, Tartumaa, Estonia (M.J.). 30. Hematology-Oncology and Stem Cell Transplantation Research Center (A. Kasaeian), Tehran University of Medical Sciences, Iran. 31. Hematologic Malignancies Research Center (A. Kasaeian), Tehran University of Medical Sciences, Iran. 32. Non-communicable Diseases Research Unit, Medical Research Council South Africa, Cape Town (A.P.K.). 33. Department of Medicine, University of Cape Town, South Africa (A.P.K., G.A.M., K.S.). 34. Department of Health Management and Health Economics, Kristiania University College, Oslo, Norway (A. Kisa). 35. Department of Health Services Policy and Management, University of South Carolina, Columbia (A. Kisa). 36. Department of Nursing and Health Promotion, Oslo Metropolitan University, Norway (S.K.). 37. Department of Medicine, Brown University, Providence, RI (D.K.). 38. Ophthalmology Department (N.M.), Iran University of Medical Sciences, Tehran. 39. Ophthalmology Department, University of Manitoba, Winnipeg, Canada (N.M.). 40. Department of Surgery, University of Virginia, Charlottesville (A.M.). 41. Center for Translation Research and Implementation Science, National Institutes of Health, Bethesda, MD (G.A.M.). 42. Faculty of General Medicine, Kyrgyz State Medical Academy, Bishkek, Kyrgyzstan (E.M.M.). 43. Department of Atherosclerosis and Coronary Heart Disease, National Center of Cardiology and Internal Disease, Bishkek, Kyrgyzstan (E.M.M.). 44. Internal Medicine Department, King Saud University, Riyadh, Saudi Arabia (Y.M.). 45. Department of Health Metrics Sciences (A.H.M., G.A.R.), University of Washington, Seattle. 46. Anatomy and Embryology Department, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania (R.I.N.). 47. Department of Cardiology, Cardio-Aid, Bucharest, Romania (R.I.N.). 48. Institute for Global Health Innovations, Duy Tan University, Hanoi, Vietnam (H.L.T.N.). 49. Center of Excellence in Behavioral Health, Nguyen Tat Thanh University, Ho Chi Minh City, Vietnam (T.H.N.). 50. Division of Cardiology (C.M.O., G.A.R.), University of Washington, Seattle. 51. Department of Medicine, Maimonides Medical Center, Brooklyn, NY (S.P.). 52. Department of Cardiology, University of Bern, Switzerland (T.P.). 53. College of Graduate Health Sciences, A.T. Still University, Mesa, AZ (A. Radfar). 54. Medichem, Barcelona, Spain (A. Radfar). 55. WHO Collaborating Centre for Public Health Education and Training (D.L.R.), Imperial College London, United Kingdom. 56. University College London Hospitals, United Kingdom (D.L.R.). 57. Department of Primary Care and Public Health (S.R.), Imperial College London, United Kingdom. 58. Public Health England, London, United Kingdom (S.R.). 59. Cardiovascular Medicine, West Virginia University, Morgantown (W.F.R.). 60. Department of Clinical Research, Federal University of Uberl ândia, Brazil (L.R.). 61. Faculty of Medicine, Ain Shams University, Cairo, Egypt (A.M.S.). 62. Department of Cardiology (S. Saadatagah), Tehran University of Medical Sciences, Iran. 63. Emergency Department, Manian Medical Centre, ERODE, Tamil Nadu, India (S. Senthilkumaran). 64. Department of Public Health, Adigrat University, Tigray, Ethiopia (B.E.T.). 65. Department of Health Economics, Hanoi Medical University, Vietnam (B.X.T.). 66. Gomal Center of Biochemistry and Biotechnology, Gomal University, Faisalabad, Pakistan (I.U.). 67. TB Culture Laboratory, Mufti Mehmood Memorial Teaching Hospital, Dera Ismail Khan, Khyber Pakhtunkhwa, Pakistan (I.U.). 68. Heart and Vascular Center, Harvard University, Boston, MA (M.V.). 69. UKK Institute, Tampere, Finland (T.J.V.). 70. School of Population Health & Environmental Sciences, King's College London, United Kingdom (C.D.A.W.). 71. Biomedical Research Council, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom (C.D.A.W.). 72. Department of Psychopharmacology, National Center of Neurology and Psychiatry, Tokyo, Japan (N.Y.).
Abstract
BACKGROUND: Nonrheumatic valvular diseases are common; however, no studies have estimated their global or national burden. As part of the Global Burden of Disease Study 2017, mortality, prevalence, and disability-adjusted life-years (DALYs) for calcific aortic valve disease (CAVD), degenerative mitral valve disease, and other nonrheumatic valvular diseases were estimated for 195 countries and territories from 1990 to 2017. METHODS: Vital registration data, epidemiologic survey data, and administrative hospital data were used to estimate disease burden using the Global Burden of Disease Study modeling framework, which ensures comparability across locations. Geospatial statistical methods were used to estimate disease for all countries, because data on nonrheumatic valvular diseases are extremely limited for some regions of the world, such as Sub-Saharan Africa and South Asia. Results accounted for estimated level of disease severity as well as the estimated availability of valve repair or replacement procedures. DALYs and other measures of health-related burden were generated for both sexes and each 5-year age group, location, and year from 1990 to 2017. RESULTS: Globally, CAVD and degenerative mitral valve disease caused 102 700 (95% uncertainty interval [UI], 82 700-107 900) and 35 700 (95% UI, 30 500-42 500) deaths, and 12.6 million (95% UI, 11.4 million-13.8 million) and 18.1 million (95% UI, 17.6 million-18.6 million) prevalent cases existed in 2017, respectively. A total of 2.5 million (95% UI, 2.3 million-2.8 million) DALYs were estimated as caused by nonrheumatic valvular diseases globally, representing 0.10% (95% UI, 0.09%-0.11%) of total lost health from all diseases in 2017. The number of DALYs increased for CAVD and degenerative mitral valve disease between 1990 and 2017 by 101% (95% UI, 79%-117%) and 35% (95% UI, 23%-47%), respectively. There is significant geographic variation in the prevalence, mortality rate, and overall burden of these diseases, with highest age-standardized DALY rates of CAVD estimated for high-income countries. CONCLUSIONS: These global and national estimates demonstrate that CAVD and degenerative mitral valve disease are important causes of disease burden among older adults. Efforts to clarify modifiable risk factors and improve access to valve interventions are necessary if progress is to be made toward reducing, and eventually eliminating, the burden of these highly treatable diseases.
BACKGROUND: Nonrheumatic valvular diseases are common; however, no studies have estimated their global or national burden. As part of the Global Burden of Disease Study 2017, mortality, prevalence, and disability-adjusted life-years (DALYs) for calcific aortic valve disease (CAVD), degenerative mitral valve disease, and other nonrheumatic valvular diseases were estimated for 195 countries and territories from 1990 to 2017. METHODS: Vital registration data, epidemiologic survey data, and administrative hospital data were used to estimate disease burden using the Global Burden of Disease Study modeling framework, which ensures comparability across locations. Geospatial statistical methods were used to estimate disease for all countries, because data on nonrheumatic valvular diseases are extremely limited for some regions of the world, such as Sub-Saharan Africa and South Asia. Results accounted for estimated level of disease severity as well as the estimated availability of valve repair or replacement procedures. DALYs and other measures of health-related burden were generated for both sexes and each 5-year age group, location, and year from 1990 to 2017. RESULTS: Globally, CAVD and degenerative mitral valve disease caused 102 700 (95% uncertainty interval [UI], 82 700-107 900) and 35 700 (95% UI, 30 500-42 500) deaths, and 12.6 million (95% UI, 11.4 million-13.8 million) and 18.1 million (95% UI, 17.6 million-18.6 million) prevalent cases existed in 2017, respectively. A total of 2.5 million (95% UI, 2.3 million-2.8 million) DALYs were estimated as caused by nonrheumatic valvular diseases globally, representing 0.10% (95% UI, 0.09%-0.11%) of total lost health from all diseases in 2017. The number of DALYs increased for CAVD and degenerative mitral valve disease between 1990 and 2017 by 101% (95% UI, 79%-117%) and 35% (95% UI, 23%-47%), respectively. There is significant geographic variation in the prevalence, mortality rate, and overall burden of these diseases, with highest age-standardized DALY rates of CAVD estimated for high-income countries. CONCLUSIONS: These global and national estimates demonstrate that CAVD and degenerative mitral valve disease are important causes of disease burden among older adults. Efforts to clarify modifiable risk factors and improve access to valve interventions are necessary if progress is to be made toward reducing, and eventually eliminating, the burden of these highly treatable diseases.
Entities:
Keywords:
aortic valve; global burden of disease; heart valve diseases; mitral valve
Authors: Jacqueline T DesJardin; Joanna Chikwe; Rebecca T Hahn; Judy W Hung; Francesca N Delling Journal: Circ Res Date: 2022-02-17 Impact factor: 17.367
Authors: Tom Kai Ming Wang; Scott D Flamm; Paul Schoenhagen; Brian P Griffin; L Leonardo Rodriguez; Richard A Grimm; Bo Xu Journal: Radiol Cardiothorac Imaging Date: 2021-08-26
Authors: David S Owens; Traci M Bartz; Petra Buzkova; Daniele Massera; Mary L Biggs; Selma D Carlson; Bruce M Psaty; Nona Sotoodehnia; John S Gottdiener; Jorge R Kizer Journal: Heart Date: 2021-06-02 Impact factor: 7.365
Authors: Petra Büttner; Lukas Feistner; Philipp Lurz; Holger Thiele; Joshua D Hutcheson; Florian Schlotter Journal: Front Cardiovasc Med Date: 2021-05-10
Authors: Sean Coffey; Ross Roberts-Thomson; Alex Brown; Jonathan Carapetis; Mao Chen; Maurice Enriquez-Sarano; Liesl Zühlke; Bernard D Prendergast Journal: Nat Rev Cardiol Date: 2021-06-25 Impact factor: 32.419